I will definitely be getting the updated vaccine in the fall.
Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start
KEY POINTS
- The U.S. Food and Drug Administration’s Covid strain selection for the next round of shots is a decisive win for Pfizer, Moderna and Novavax.
- The FDA advised the three pharmaceutical companies to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5.
- The agency’s decision puts the vaccine makers on track to deliver updated coronavirus jabs in time for the fall and winter.
- The timely delivery of new vaccines will position each pharmaceutical company to compete in the commercial market.
The
U.S. Food and Drug Administration’s Covid
strain selection for the next round of shots puts
Pfizer,
Moderna and
Novavax on track to deliver new jabs in time for the fall — a decisive win for the vaccine makers as they gear up to
compete against one another.
The FDA on Friday
advised the three companies to manufacture
single-strain jabs targeting the omicron subvariant
XBB.1.5, one of the most immune-evasive Covid variants to date.
That strain accounted for nearly 40% of all Covid cases in the U.S. in early June, but that proportion is slowly declining, according to
data from the Centers for Disease Control and Prevention.
The FDA's strain selection puts Pfizer, Moderna and Novavax on track to deliver updated coronavirus shots in time for the fall.
www.cnbc.com